ArticleToxicology research2025
Synthesis, in-vitro,
Article in Toxicology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Curcumin is a well-known anticancer agent used for many malignancies; however, its low bioavailability and solubility limit its use in clinical applications. To enhance its efficacy, we synthesized a novel curcumin-benzoquinone analog, JWB1 (3), and evaluated its anticancer potential against triple-negative breast cancer (TNBC) in vitro. We designed JWB1 (3) and structurally identified it using NMR, FTIR, MS, and UV-Vis techniques. The MTT assay was used to evaluate JWB1 (3) cytotoxicity in the MDA-MB-231, MCF-7, and HUVEC cell lines. Flow cytometry was used to examine apoptotic activation and reactive oxygen species (ROS) levels. Global DNA methylation was measured using an ELISA kit. Docking studies and molecular dynamics simulations revealed potential JWB1 (3) interactions with double-stranded DNA (dsDNA). JWB1 (3) showed selective cytotoxicity towards MDA-MB-231 cells (IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.